Black Diamond Therapeutics Inc (BDTX)

NASDAQ
9.50
-0.40(-4.04%)
After Hours
9.90
+0.40(+4.21%)
- Real-time Data
  • Volume:
    660,803
  • Bid/Ask:
    9.64/10.00
  • Day's Range:
    9.49 - 10.07

BDTX Overview

Prev. Close
9.9
Day's Range
9.49-10.07
Revenue
-
Open
9.9
52 wk Range
8.75-37.5
EPS
-2.91
Volume
660,803
Market Cap
344.03M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
380,511
P/E Ratio
-
Beta
-
1-Year Change
-69.68%
Shares Outstanding
36,213,654
Next Earnings Date
Nov 16, 2021
What is your sentiment on Black Diamond Therapeutics Inc?
or
Market is currently closed. Voting is open during market hours.

Black Diamond Therapeutics Inc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellSellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell

Black Diamond Therapeutics Inc Company Profile

Black Diamond Therapeutics Inc Company Profile

Employees
73

Black Diamond Therapeutics, Inc., a biotechnology company, discover and develops small molecule, tumor-agnostic therapies. Its lead product candidate is BDTX-189, an irreversible small molecule inhibitor that is designed to block the function of family of oncogenic proteins defined by driver mutations across a range of tumor types, and which affect the epidermal growth factor receptor (EGFR), the tyrosine-protein kinase, or human epidermal growth factor receptor 2. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including allosteric and canonical EGFR mutations; and various early stage pipeline programs of allosteric mutations in kinases related to cancer and/or rare genetic diseases. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Read More
  • Next 14.8
    0
    • Now 13.30
      2
      • Don't buy it it will go down and down really bad news
        2
        • 13.9
          0
          • basically on sale
            1
            Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
            Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.